{"schema_version":"secwatch.filing_event.v1","accession":"0001376339-25-000044","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.102167+00:00","generated_at":"2026-05-23T02:09:10.064767+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MiMedx Q1 net sales $88M (+4% YoY); GAAP EPS $0.05; reaffirms high single-digit growth outlook","bullets":["Net sales $88M (+4% YoY); GAAP net income $7M ($0.05 EPS); Adj. EBITDA $17M (20% margin).","Gross margin fell to 81% from 85% on product mix; Surgical products grew 16%, Wound fell 2%.","Cash $106M; net debt $0; 2025 outlook: high single-digit sales growth and >20% Adj. EBITDA margin.","CEO calls LCD delay disappointing; added CELERA product as contingency for affected settings.","SG&A rose to $60M from $55M on higher commissions, salaries, and legal/regulatory costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001376339-25-000044","json":"https://secwatch.observer/filing/0001376339-25-000044.json","markdown":"https://secwatch.observer/filing/0001376339-25-000044.md","text":"https://secwatch.observer/filing/0001376339-25-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000137633925000044/0001376339-25-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000137633925000044/mdxg-20250430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:09:10.064767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}